Streetbeat News

Price Targets

LRCX

Five financial analysts have recently updated their ratings on Lam Research (NASDAQ:LRCX), with a mix of opinions ranging from bullish to indifferent. The average 12-month price target for LRCX is now $734.00, up from the previous $670.00, with a high estimate of $800.00 and a low of $700.00. Analysts from Barclays, Morgan Stanley, Redburn Atlantic, JP Morgan, and B. Riley Securities have made adjustments to their ratings and price targets. Lam Research, a major semiconductor equipment manufacturer, has shown a revenue decline of -31.38% over the last quarter but maintains a strong net margin of 25.48% and an ROE of 10.92%. The company's debt-to-equity ratio is 0.62, indicating a higher level of debt.

Portfolio Pulse from Benzinga Insights

January 16, 2024 | 7:01 pm

PG

Procter & Gamble (NYSE:PG) received mixed analyst ratings over the last three months, with 1 bullish, 2 somewhat bullish, and 2 indifferent. The average 12-month price target is $161.8, up from $158.33. Barclays and Stifel adjusted their price targets, while Jefferies and DZ Bank announced new ratings. P&G's financials show strong revenue growth and net margin, but below-average ROE. The company's market cap and ROA are above industry standards, and it has a conservative debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 16, 2024 | 7:01 pm

TAP

Molson Coors Beverage (NYSE:TAP) has received consistent 'Hold' ratings from five analysts in the past three months, with no change in sentiment in the last 30 days. The average 12-month price target for TAP has risen to $64.4, up from $61.00, with a high estimate of $70.00 and a low of $58.00. Analysts from Barclays, HSBC, Jefferies, Wedbush, and Deutsche Bank have provided recent evaluations, with some adjusting their price targets. Molson Coors, known for brands like Miller and Coors, has shown a revenue growth of 12.37% and a high net margin of 13.06%, but faces challenges with a below-average ROA and high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 16, 2024 | 7:01 pm

CYBR

Truist Securities analyst Ki Bin Kim has reaffirmed a Buy rating on CyberArk Software (NASDAQ:CYBR) and increased the price target from $210 to $250, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 7:01 pm

BXP

Boston Properties (NYSE:BXP) received mixed analyst ratings over the last three months, with 1 bullish and 3 indifferent ratings. The average 12-month price target for BXP is now $73.5, up 12.21% from the previous $65.50. Analysts from Truist Securities and Piper Sandler adjusted their price targets, while Jefferies raised their target significantly. Boston Properties has shown a positive revenue trend with a growth rate of 4.27% as of September 30, 2023, but has a negative net margin of -13.57% and an ROE of -1.89%. The company's debt-to-equity ratio is high at 2.69.

Portfolio Pulse from Benzinga Insights

January 16, 2024 | 7:00 pm

CHCT

Community Healthcare Trust Inc (NYSE:CHCT) has been analyzed by 4 analysts, with ratings ranging from bullish to indifferent. The average 12-month price target is now $35.75, down from $41.50, with a high estimate of $40.00 and a low of $32.00. Analysts from Truist Securities, Piper Sandler, and Evercore ISI Group have all lowered their price targets. The company's financial performance shows a revenue growth of 15.83%, a net margin of 9.99%, an ROE of 0.56%, an ROA of 0.31%, and a debt-to-equity ratio of 0.78.

Portfolio Pulse from Benzinga Insights

January 16, 2024 | 7:00 pm

KMB

Five analysts have updated their ratings on Kimberly-Clark (NYSE:KMB) over the past three months, with a mix of opinions. The average 12-month price target is now $126.2, up from $125.50, with a high estimate of $146.00 and a low of $115.00. Analysts' actions include both upgrades and downgrades, reflecting a nuanced view of the company's prospects. Kimberly-Clark's financials show strong net margin and ROE but a high debt-to-equity ratio, indicating potential financial risk.

Portfolio Pulse from Benzinga Insights

January 16, 2024 | 7:00 pm

CRWD

Truist Securities analyst Patrick Scholes has reaffirmed a Buy rating on CrowdStrike Holdings (NASDAQ:CRWD) and increased the price target from $230 to $290.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 6:59 pm

CUZ

Truist Securities analyst Michael Lewis has maintained a Buy rating on Cousins Properties (NYSE:CUZ) but reduced the price target from $27 to $26.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 6:56 pm

CHCT

Truist Securities analyst Michael Lewis has maintained a Buy rating on Community Healthcare Trust Incorporated (NYSE:CHCT) but has reduced the price target from $36 to $35.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 6:55 pm